Barclays Maintains Overweight on Elevance Health, Lowers Price Target to $611
Portfolio Pulse from Benzinga Newsdesk
Barclays analyst Andrew Mok maintains an Overweight rating on Elevance Health (NYSE:ELV) but lowers the price target from $621 to $611.

July 18, 2024 | 3:26 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Barclays analyst Andrew Mok maintains an Overweight rating on Elevance Health but lowers the price target from $621 to $611.
The Overweight rating suggests a positive outlook on Elevance Health, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100